Healthcare Strategies

FDA ends GLP-1 compounding for semaglutide, tirzepatide

Listen Later

FDA’s removal of GLP-1 drugs from the shortage list ends supplemental compounding, shifting patient access back to branded semaglutide and tirzepatide.

Featuring: Sara Heath, executive editor, Xtelligent Healthcare

Alivia Kaylor, senior editor of Pharma Life Sciences, Xtelligent Healthcare

In today’s episode, we’ll cover…

  • The end of GLP-1 compounding creates a significant access barrier for millions of patients seeking weight management solutions
  • Financial inequity deepens as patients transition from affordable compounded options to expensive branded medications
  • Future innovation in oral GLP-1 formulations offers hope but remains constrained by long-term patent protections

    • and more!

    References:

    • Anticipating the healthcare reach of GLP-1 receptor agonists
    • Are compounded GLP-1 drugs safe?
    • FDA winds down GLP-1 compounding policies

      • To learn more about GLP-1s, check out our Pharma Life Sciences and Patient Engagement sites.

      To watch the video clips of our podcast, subscribe to our YouTube channel, @HealthcareStrategies.

      ...more
      View all episodesView all episodes
      Download on the App Store
      Healthcare StrategiesBy Informa TechTarget
      • 4.7
      • 4.7
      • 4.7
      • 4.7
      • 4.7

      4.7

      34 ratings